Abstracts tagged "Ankylosing spondylitis (AS) and rheumatoid arthritis (RA)"

Abstract Number: 2523 • 2014 ACR/ARHP Annual Meeting
Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Omer Nuri Pamuk¹, Umut Kalyoncu², Kenan Aksu³, Salim Donmez⁴, Yavuz Pehlivan⁵, Yonca Cagatay⁶, Ahmet Omma⁷, Orhan Küçükşahin⁸, Gozde Yildirim Cetin⁹, Özün Bayındır¹⁰, Fatih Yildiz¹¹, Ayse Balkarli¹², Levent Kilic¹³, Necati Cakir¹⁴, Bunyamin Kisacik¹⁵, Ahmet Mesut Onat¹⁵, Mustafa Ferhat Özgür¹⁶, Veli Cobankara¹² and Mehmet Sayarlioglu¹⁷, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Hacettepe University School of Medicine, Ankara, Turkey, ³Rheumatology, Ege University School of Medicine, Izmir, Turkey, ⁴Department of Rheumatology, Trakya University School of Medicine, Edirne, Turkey, ⁵Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, ⁶Department of Rheumatology, Bilim University Faculty of Medicine, Istanbul, Turkey, ⁷ROMATOLOJI SERVISI, IST. UNV. TIP FAK. HASTANESI, ISTANBUL, Turkey, ⁸Trakya University Medical Faculty, İstanbul, Turkey, ⁹Ismet Pasa Mah, None, Kahramanmaras, Turkey, ¹⁰Ege University Medical Faculty, Izmir, Turkey, ¹¹Rheumatology, Cukurova University, School of Medicine, Adana, Turkey, ¹²Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey, ¹³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁴Fatih Sultan Mehmet State Hospital, İstanbul, Turkey, ¹⁵Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ¹⁶Uludag University Medical Faculty, Bursa, Turkey, ¹⁷Rheumatology, KahramanmarasSutçü ImamUniversity School of Medicine, Kahramanmaras, Turkey
Background/Purpose Biologic drugs including anti-TNF agents have been used in the treatment of secondary amyloidosis, however, there is no controlled study concerning the efficacy of…
Abstract Number: 1369 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Porphyromona Gingivalis Serology In Rheumatoid Arthritis and Non-Rheumatoid Inflammatory Disease
Mélanie Rinaudo-Gaujous¹, Adeline Moreau¹, Vincent Blasco-Baque², Xavier Roblin³, Christian Genin¹, Thierry Thomas⁴, Stéphane Paul¹ and Hubert Marotte⁵, ¹Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ²Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, ³Department of gastroenterology, Hôpital Nord, Saint-Etienne, France, ⁴INSERM U1059 and University Hospital, Saint-Etienne, France, ⁵INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France
Background/Purpose: Periodontal disease (PD) is associated mainly with rheumatoid arthritis (RA), but recent data suggest an association with ankylosing spondylitis (AS). Role of Porphyromonas gingivalis…
Abstract Number: 1797 • 2012 ACR/ARHP Annual Meeting
Wnt Signaling Pathway Status, Determined by Serum Dkk-1 and R-Spondin 1 Levels, in Rheumatoid Arthritis and Ankylosing Spondylitis
Byoong Yong Choi¹, Hyon Joung Cho¹, Eun Ha Kang², Yeong Wook Song³ and Yun Jong Lee¹, ¹Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Dickkopf-1 (Dkk-1), known as inhibitor of Wnt signaling pathway, is involved in joint damage in inflammatory arthritis. While R-spondin 1 (Rspo1) reported to protect…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].